Peter Gibson Australia

Professor Peter Gibson is a Past President of the Thoracic Society of Australia and New Zealand, serving from 2015 to 2017. He is a respiratory physician and clinical researcher. Professor Gibson is Co-Director of the University of Newcastle’s Priority Research Centre for Treatable Traits and a leader in the Hunter Medical Research Institute’s Breathing and Lung Health Research Program. He also leads the Australasian Severe Asthma Registry hosted by TSANZ. His internationally recognised research includes inflammatory subtypes of asthma and cough, airway biomarkers, neurogenic mechanisms and laryngeal dysfunction in chronic cough, and multidimensional assessment and management of complex airway disorders. He is a member of the Australian Academy of Health and Medical Scientists and received the European Respiratory Society Gold Medal in Asthma in 2018.”
Job Title
Professor, School of Medicine and Public Health
Faculty / Department / Division
medicine
Institution / Organisation
University of Newcastle

20 November 2026, Friday

Time Session
11:00
12:00
Aisya Natasya Musa Chairperson Malaysia
Diahn-Warng Perng Chairperson Taiwan
  • Azza Omar Speaker Malaysia
  • Anthony Yii Speaker Singapore
    Acute asthma exacerbations are conventionally treated with a standard course of systemic corticosteroids, regardless of the underlying inflammatory phenotype. However, increasing evidence suggests that exacerbations are biologically heterogeneous, with differences in corticosteroid responsiveness between type 2-high and type 2-low inflammation. Repeated corticosteroid exposure also contributes to substantial long-term morbidity and healthcare costs. This presentation examines the rationale and emerging evidence for biomarker-directed treatment of acute asthma exacerbations. Transcriptomic studies demonstrate differential corticosteroid effects across inflammatory pathways, while clinical studies suggest that physiological responses may vary according to inflammatory phenotype. Findings from a randomized controlled trial evaluating blood eosinophil-guided corticosteroid duration in hospitalized asthma exacerbations will be presented, alongside emerging evidence for biologic therapies during acute exacerbations. Together, these findings support a shift towards more individualized exacerbation management, with the potential to reduce unnecessary corticosteroid exposure while maintaining clinical effectiveness. Larger confirmatory trials are needed before widespread implementation.
  • Peter Gibson Speaker Australia
  • Q&A
Ballroom 1, Lower Ground Floor

22 November 2026, Sunday

Time Session
09:00
10:30
Andrea Ban Chairperson Malaysia
Ballroom 1, Lower Ground Floor